Swift Configuration defines an abstraction layer between configuration readers and providers. Applications and libraries read configuration through a consistent API, while the actual provider is set ...

BioTime will report earnings from Q4 on March 7. Analysts predict BioTime will release losses per share of $0.043. Go here to track BioTime stock price in real-time on Markets Insider. BioTime ...

Azure App Configuration is a managed service that helps developers centralize their application configurations simply and securely. The JavaScript configuration provider library enables loading ...

ASP.NET Core configuration providers read configuration data from common sources such as JSON files and databases. But you can use other sources by creating custom configuration providers. We use ...

BIOTIME PHARMACEUTICALS PRIVATE LIMITED is a Private Limited Company, governed by the Companies Act as a company limited by shares. Classified as a Non-government company, it is registered under the ...

NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer ...

BIOTIME HEALTHCARE PRIVATE LIMITED is a Private Limited Company, governed by the Companies Act as a company limited by shares. Classified as a Non-government company, it is registered under the ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, announced the pricing of ...

BioTime has received US$43 million (€37 million) from Juvenescence for a stake in AgeX and plans to spin the cell therapy subsidiary out in September. In April 2017, Californian late-stage biotech ...

BioTime to receive $21.6 million in cash and $21.6 million in a convertible/redeemable note for 14.4 million shares of AgeX Therapeutics ALAMEDA, Calif.--(BUSINESS ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has been awarded a grant of $743 ...